Liver cancer trial withdrawn before it began: black seed extract study never enrolled patients

NCT ID NCT06217094

Terminated Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This was a planned Phase 1 study to test NP-101, a drug made from black seed, in people with liver cancer that cannot be removed by surgery. Participants would have taken NP-101 daily for 28 days before receiving standard Y-90 radiation treatment. The goal was to find the safest dose and see if NP-101 could improve the immune response against the cancer. However, the trial was withdrawn before enrolling any patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NP-101 (black seed extract)
What this could lead to: If it worked, NP-101 might boost the immune system to help control liver cancer when combined with standard Y-90 treatment.
What could go wrong: This trial was withdrawn before any patients enrolled, so no data exists. It was a very early Phase 1 safety study, and many such studies never lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

University of Florida

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.